Core Insights - Ocumetics Technology Corp. announced positive one-month results from Group 1 of its first-in-human clinical study for the Ocumetics Accommodating Intraocular Lens, showing promising visual outcomes [1][4][5] Group 1 Surgery Results - Group 1 surgeries were completed in August and September 2025, with all patients showing Corrected Distance Visual Acuity (CDVA) between 20/32 and 20/25 after one month [2][3] - The visual gains observed are particularly encouraging given that patients began the study with significantly impaired distance vision due to cataracts [4] Company Statements - The President and CEO expressed excitement over the results, noting that they have met or exceeded internal expectations and demonstrate the transformative potential of the Ocumetics Lens [4][6] - The Chief Medical Officer highlighted the remarkable achievement of 20/32 or better vision shortly after surgery, emphasizing the lens's optical quality and stability [5] Future Plans - Planning for Group 2 surgeries is currently underway, with updates expected in the coming weeks [7] - The company aims to maintain momentum as it progresses to subsequent patient groups [6] Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, aiming to transform ophthalmology with innovative intraocular lenses and vision-enhancing technologies [8][9]

Core Insights - Ocumetics Technology Corp. is set to present at the Centurion One Capital 3rd Annual Bahamas Summit, an exclusive event for growth companies and investors [1][6] - The presentation will focus on the Ocumetics Accommodating Intraocular Lens and recent first-in-human study results [2][5] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company dedicated to advanced vision correction solutions aimed at enhancing patients' quality of life [4] - The company is currently in the early feasibility study phase for a revolutionary intraocular lens designed to function within the eye's natural lens compartment, potentially eliminating the need for corrective lenses [5] Event Details - The Centurion One Capital 3rd Annual Bahamas Summit will take place from October 28th to 29th, 2025, at the Rosewood Baha Mar Hotel in Nassau, Bahamas [1][6] - The event will feature company presentations, one-on-one investor meetings, and dynamic panels, providing networking opportunities for participants [6]

Core Insights - Ocumetics Technology Corp. is hosting a webinar to discuss one-month patient results from its initial Group 1 patients who received the Ocumetics Accommodating Intraocular Lens [1][2] - The webinar will cover updates on the first-in-human study and future steps in the development process [2][3] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patient quality of life [4] - The company is developing innovative intraocular lenses designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses [5] Webinar Details - The webinar is scheduled for October 15, 2025, at 6:00 PM ET, featuring CEO Dean Burns [2] - Key topics will include one-month postoperative patient results, next steps for the Ocumetics study, and a live Q&A session [6]

Core Insights - Ocumetics Technology Corp. has reported promising one-month safety and vision performance results for its Ocumetics Accommodating Intraocular Lens, marking a significant milestone in ophthalmology [1][2]. Group 1: Clinical Results - The initial patients have achieved functional distance vision of 20/40 or better without glasses after one month, with encouraging signs of near vision performance and no complications [2]. - The early results are expected to improve as patients adapt and the clinical program progresses [2]. Group 2: Company Overview - Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [3]. - The company is in the first-in-human early feasibility study phase for its innovative intraocular lens technology, which is designed to eliminate the need for corrective lenses [4][5]. Group 3: Research Focus - The clinical protocol includes three patient groups, evaluating safety, surgical techniques, and distance vision correction capabilities of the Ocumetics Lens [3][4].

Core Insights - Ocumetics Technology Corp. has successfully completed its second surgical day in Mexico City as part of its clinical study for the Ocumetics Accommodating Intraocular Lens [1] - All procedures were completed safely, reinforcing confidence in the safety profile of the Ocumetics Lens and the surgical protocol [2] - The company is excited about the momentum in its clinical program, with Group 1 patient surgeries now completed [3] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [4] - The company is in the preclinical study phase of a transformative technology for the ophthalmic industry, developing an intraocular lens that may eliminate the need for corrective lenses [5] Clinical Study Design - The clinical protocol is designed to evaluate three patient groups with specific primary and secondary endpoints [4] - Key areas of evaluation include safety, distance vision correction, product handling and surgical delivery, and near reading ability [6]

Core Insights - Ocumetics Technology Corp. has completed one-month postoperative examinations of the first patients implanted with the Ocumetics Accommodating Intraocular Lens in Mexico City on August 15, 2025 [1][2] - The company is currently focusing on Group 1 patients, with surgeries for the second and final day scheduled for September 24, 2025 [3] - The clinical protocol is designed to evaluate safety, distance vision correction, product handling, and near reading ability [7] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company dedicated to advanced vision correction solutions aimed at enhancing patient quality of life [4] - The company is in the preclinical study phase of a new intraocular lens technology that may eliminate the need for corrective lenses by allowing natural muscle activity to shift focus [5]

Core Insights - Ocumetics Technology Corp. has successfully completed the one-week postoperative examination of the first patients implanted with the Ocumetics Accommodating Intraocular Lens, with all patients recovering well and no complications observed [1][3] - The company is now recruiting additional individuals to complete the first group of patients for the Ocumetics Lens [2] - The Ocumetics Lens aims to redefine vision correction by allowing the eye's natural muscular activity to focus on both distant and near objects without the need for glasses or contact lenses after cataract surgery [3][5] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions to enhance patients' quality of life [4] - The company is dedicated to transforming the field of ophthalmology through innovative research and development of state-of-the-art intraocular lenses and other vision-enhancing technologies [4] Product Development - The Ocumetics Lens is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses by providing clear vision at all distances [5] - The company is currently in the preclinical study phase for this groundbreaking technology in the ophthalmic industry [5]